Teva Sells Paragard For $1.1B

Sep 12, 2017

After introducing its new CEO, Teva Pharmaceutical announced that it will sell its contraceptive brand Paragard to Cooper Cos for $1.1 billion. The deal includes Teva’s manufacturing facility in Buffalo, New York.

According to the drugmaker, the sale of the business is an initial step in the planned divestment of non-core assets in order to repay a portion of its $35 billion in debt.

Teva said it expects to generate at least $2 billion by year end from the sale of the remaining assets of its global women’s health business, as well as its oncology and pain businesses in Europe.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments